Abstract: The present invention relates to antibody compositions directed to Interleukin 1 Receptor Accessory Protein (IL1RAP) and their use in the treatment and diagnosis of diseases associated with IL1RAP, such as inflammatory, autoimmune, autoinflammatory and neoplastic disorders.

Abstract: In accordance with various embodiments, systems and methods are provided for co-locating execution logic and state data in a distributed and clustered environment. Such a system can include a plurality of applications, executing on one or more application servers, including an event broker which identifies state data required by an actor, a database which identifies an application server where such state data is cached; and a co-location module which instantiates the actor on the application server where such state data is cached. The method includes identifying state data required by a transaction, identifying an application server where such state data is cached, instantiating execution logic for processing the transaction on the application server where such state data is cached, and executing said execution logic for processing the transaction on the application server where such state data is cached thereby providing predictable low execution latency.

Abstract: This invention relates to a feed out device relating to a reversible feeder tube, i.e. a reclaimer, intended for bulk product, in particular a feeder tube, which includes a cylindrical drum or tube in which there are accommodated a large number of inlet openings distributed along the length of the tube, and a screw conveyor disposed coaxially with the tube within the tube. A device is provided for rotating the tube about its axis, and a device for rotating the screw conveyor relative to the tube. A device is provided for moving the feeder tube in the lateral direction, within a silo arrange to feed out bulk product into an outlet space, wherein an outer end of the feeder tube protrudes through an opening in the silo into a side space. The tube has at least one inlet opening disposed in the space. Adjacent the outer end there is arranged a feeding device arranged to assist in feeding bulk material into the inlet.

Abstract: In accordance with various embodiments, systems and methods are provided for co-locating execution logic and state data in a distributed and clustered environment. Such a system can include a plurality of applications, executing on one or more application servers, including an event broker which identifies state data required by an actor, a database which identifies an application server where such state data is cached; and a co-location module which instantiates the actor on the application server where such state data is cached. The method includes identifying state data required by a transaction, identifying an application server where such state data is cached, instantiating execution logic for processing the transaction on the application server where such state data is cached, and executing said execution logic for processing the transaction on the application server where such state data is cached thereby providing predictable low execution latency.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: There is described a crushing plant and a method for controlling the same. The crushing plant involves a gyratory crusher (1) with means for controlling a minimum gap in a crushing chamber, and is driven by a diesel engine (18). A load value is retrieved from the diesel engine e.g. by means of a J1939 interface. If the retrieved value exceeds a predetermined threshold value, the minimum gap is increased. Thereby it can be avoided that the diesel engine stalls; such that continuous operation of the crushing plant may be ensured.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: There is described a crushing plant and a method for controlling the same. The crushing plant involves a gyratory crusher (1) with means for controlling a minimum gap in a crushing chamber, and is driven by a diesel engine (18). A load value is retrieved from the diesel engine e.g. by means of a J1939 interface. If the retrieved value exceeds a predetermined threshold value, the minimum gap is increased. Thereby it can be avoided that the diesel engine stalls; such that continuous operation of the crushing plant may be ensured.

Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV?, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.

Abstract: A feeder tube for bulk product, including a tube in which there are inlet openings distributed along the length of the tube. A screw conveyer is disposed axially within the tube. The tube rotates about its axis, the screw conveyer rotates relative to the tube and the feeder tube moves in the lateral direction. Activators form projections on the outer side of the tube and are disposed on the tube near the inlet openings. In each cross-section along at least 40% of the length of the tube, there are at least two inlet openings. At least two activators are also positioned in each cross-section. For a feeder tube having a desired average volumetric capacity (V′) the slot width (d) of the majority of the openings is V′˜dn, wherein n is between 2-3. The total sum of the width (&Sgr;d) of all openings in each-section is between 150-700 mm.

Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, referably TCRV&bgr;, and T cell activation has been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In a preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs.